Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
85558 trials found · Page 53 of 4278
-
New drug combo aims to stop breast Cancer's second act
Disease control Recruiting nowThe JCOG2313 trial is a multicenter, randomized, phase III study designed to evaluate the efficacy and safety of adjuvant abemaciclib in combination with endocrine therapy versus endocrine therapy alone in patients with hormone receptor (HR)-positive, HER2-negative breast cancer …
Phase: PHASE3 • Sponsor: Japanese Foundation for Cancer Research • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Virus vs. superbug: new weapon tested for deadly heart infections
Disease control Recruiting nowInfective endocarditis (IE) is an endocardial lesion caused by bacterial and/or fungal infection that most commonly affects the heart valves and/or the endocardium around implanted intracardiac devices. In general, IE is classified as a rare disease, but there has been a steady i…
Phase: PHASE3 • Sponsor: University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba) • Aim: Disease control
Last updated Apr 13, 2026 20:16 UTC
-
Engineered immune cells battle blood cancers after transplant
Disease control Recruiting nowThe goal of this clinical trial is to test BSB-1001 which is a new type of cellular therapy to treat blood cancers (AML, ALL and MDS). It will evaluate the safety of BSB-1001 and also determine whether it works to prevent relapse of your cancer.
Phase: PHASE1, PHASE2 • Sponsor: BlueSphere Bio, Inc • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
New pill aims to put the brakes on Alzheimer's decline
Disease control Recruiting nowThe goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as…
Phase: PHASE3 • Sponsor: Annovis Bio Inc. • Aim: Disease control
Last updated Apr 13, 2026 20:16 UTC
-
Brain cancer breakthrough? Triple-Threat treatment trial seeks to extend lives
Disease control Recruiting nowThis is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newl…
Phase: PHASE3 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC
-
New drug aims to prevent lifelong lung damage in tiniest babies
Prevention Recruiting nowThis is a randomized, parallel-group, double-blind, placebo-controlled multicenter phase 2b/3 study with an adaptive seamless design. The goal fo this study is to determine if an investigational drug, Zelpultide Alfa, can reduce the occurrence of Bronchopulmonary Dysplasia (BPD)…
Phase: PHASE2, PHASE3 • Sponsor: Airway Therapeutics, Inc. • Aim: Prevention
Last updated Apr 24, 2026 07:44 UTC
-
New hope for aggressive lung cancer: experimental drug combo enters final testing
Disease control Recruiting nowThis is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untr…
Phase: PHASE3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Apr 24, 2026 07:43 UTC
-
Major trial aims to extend life for deadly brain tumor patients
Disease control Recruiting nowBackground: Glioblastoma (GBM) is notoriously difficult to treat, with current therapies often extending life by only a few months. The standard treatment involves surgery followed by radiation and chemotherapy with Temozolomide (TMZ). The efficacy of TMZ, however, is significant…
Phase: PHASE3 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
New hope for esophageal cancer: can a year of immunotherapy keep the disease at bay?
Disease control Recruiting nowThe goal of this clinical trial is to learn if concurrent chemoradiotherapy followed by immunotherapy as maintenance therapy works to treat locally advanced esophageal squamous cell cancer in adults.
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Scientists reprogram Patient's own cells to fight incurable blood cancer
Disease control Recruiting nowThe mail purpose of this study is to estimate the safety and the efficacy of anti-BCMA CAR- T cell immunotherapy for adults with relapsed or refractory multiple myeloma
Phase: PHASE1, PHASE2 • Sponsor: Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology • Aim: Disease control
Last updated Apr 23, 2026 12:43 UTC
-
New pill shows promise for painful skin disease in major trial
Disease control Recruiting nowThe purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 09, 2026 19:31 UTC
-
Engineered immune cells take aim at childhood cancer in new trial
Disease control Recruiting nowThis Phase 1/2 trial aims to determine the safety and feasibility of administration of autologous chimeric antigen receptor (CAR) T cells targeting the human Anaplastic Lymphoma Kinase (ALK) receptor in pediatric subjects with relapsed or refractory neuroblastoma (NB). The trial…
Phase: PHASE1, PHASE2 • Sponsor: Roberto Chiarle • Aim: Disease control
Last updated Apr 24, 2026 07:42 UTC
-
Off-the-Shelf immune cell therapy tested for tough blood cancers
Disease control Recruiting nowThe T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response
Phase: PHASE2 • Sponsor: Wugen, Inc. • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC
-
New drug combo tested to boost leukemia transplant success
Disease control Recruiting nowThis project is a prospective, single-center, randomized controlled clinical study. The subjects were high-risk or relapsed/refractory AML or ALL patients aged ≤ 65 years diagnosed by bone marrow cell morphology, immunology, genetics and therapeutic efficacy evaluation. The TmBU …
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Apr 09, 2026 19:32 UTC
-
New hope for kids with untreatable autoimmune diseases
Disease control Recruiting nowthis is an investigator-initiated trial aimed at evaluating the efficacy and safety of anti-CD19/BCMA CAR-NK Cells in Patients With B cell mediated autoimmune disease.
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
New hope for aggressive brain cancer: experimental drug trial opens
Disease control Recruiting nowThe goal of Phase 1 of this clinical research study is to find the highest tolerable dose and the recommended Phase 2 dose of ivonescimab that can be given to patients who have recurrent glioblastoma. The goal of Phase 2 of this clinical research study is to learn if the recomme…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
State-Funded trial tests 'Magic Mushroom' therapy for Veterans' trauma
Disease control Recruiting nowThe principal investigator for this study plans to build upon the psilocybin-assisted therapy intervention used in prior completed trials to conduct an open-label trial of two psilocybin administration sessions combined with psychotherapy to investigate the safety, tolerability, …
Phase: PHASE2 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Apr 20, 2026 16:19 UTC
-
Two-Pronged attack on advanced head and neck cancer enters major trial
Disease control Recruiting nowFicerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in …
Phase: PHASE2, PHASE3 • Sponsor: Bicara Therapeutics • Aim: Disease control
Last updated Apr 09, 2026 19:33 UTC
-
Major cancer trial tests new weapon against aggressive lymphoma
Disease control Recruiting nowThe purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 13, 2026 20:18 UTC
-
New Two-Drug attack on childhood leukemia aims for deeper remission
Disease control Recruiting nowThis is a Phase II clinical trial testing the use of two antigen-directed therapies, inotuzumab and blinatumomab, as part of induction therapy for children and young adults with newly diagnosed B-cell precursor acute lymphoblastic leukemia and lymphoma. Primary Objective * To a…
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC